Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naive healthcare workers.

ABSTRACT:

Background

Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what other factors affect responsiveness.

Methods

We measured IgA, IgG and IgM levels against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens from the wild-type and S from the Alpha, Beta and Gamma variants of concern, after BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccination in a cohort of health care workers (N=578). Neutralizing capacity and antibody avidity were evaluated. Data were analyzed in relation to COVID-19 history, comorbidities, vaccine doses, brand and adverse events.

Findings

Vaccination induced robust IgA and

SUBMITTER: Moncunill G 

PROVIDER: S-EPMC8752368 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature